Skip to content

Efficiency of Physiotherapeutic Care in Parkinson's Disease

Efficiency of Physiotherapeutic Care in Parkinson's Disease

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00330694
Enrollment
708
Registered
2006-05-29
Start date
2006-05-31
Completion date
2007-07-31
Last updated
2008-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Physical Therapy, Organisation of care

Brief summary

In the course of their disease, most patients with Parkinson's Disease (PD) face mounting mobility deficits, including difficulties with walking, balance, posture and transfers. This frequently leads to (fear of) falls, injuries, loss of independence, and inactivity which causes social isolation and increases the risk of osteoporosis or cardiovascular disease. These mobility deficits are difficult to treat with drugs and neurosurgery. However, physiotherapy is deemed effective in improving mobility deficits in PD. Physiotherapy is widely prescribed for this purpose in the Netherlands. Yet, the efficiency of current usual care physiotherapy can be questioned, for two reasons. First, the referral process seems inadequate because patients are mainly referred by neurologists who often lack insight into the (im-)possibilities of physiotherapy for PD. Consequently, patients with a real need for physiotherapy are not always referred (undertreatment), whereas others without a real need are (overtreatment). Furthermore, most therapists treating PD patients are not specifically trained in treating these patients. This is not surprising because average therapists rarely treat more than two patients per year in their practice. Therefore, patients who are being referred probably receive suboptimal treatment. The objective of this study is to evaluate whether the efficiency of physiotherapeutic care for patients with Parkinson's disease can be improved, at a reduced cost, by targeting two key elements of the current care system: a) inadequate referral by neurologists; b) suboptimal treatment by physiotherapists. We expect that optimal referral combined with expert treatment will increase the efficiency, as reflected by increased health benefits for patients at equal or reduced costs'.

Detailed description

Design In a Cluster Randomised Trial, 16 clusters will be randomly allocated to either network care (8 clusters with an altered organisation of physiotherapeutic care) or usual care (8 clusters with unchanged organisation of physiotherapeutic care). Clusters are formed by all PD patients living in the communities connected to participating regional hospitals in the 16 clusters. The health care intervention in the experimental group has two elements: (a) an improved quality of referrals by neurologists; and (b) an improved quality of interventions by physiotherapists. Brief description Network Care: In each of the Network Care clusters, 5 to 7 motivated therapists are selected to enroll in a regional ParkNet and consequently trained. Training is focused at correct use of the evidence-based guidelines for physiotherapy in PD (Keus et al, 2006). This training consists of a 5-day competence-oriented course, web-based continues education supported by seminars, and use of a PD specific electronic patient record. Neurologists are informed about indications for referral to physiotherapy. Improved communication between neurologist and ParkNet therapists is initiated and supported. Following implementation of the health care change, PD patients attending the neurological outpatient clinics of the individual hospitals within the clusters will be asked to participate. During a period of 6 months, PD patients will enrol in the study. Enrollees will be followed for 6 months to measure the use and quality of physiotherapy, patient health benefit and satisfaction, and costs.

Interventions

OTHERParkNet

Development of a network of dedicated physiotherapist with specific expertise in Parkinson's Disease and structured referrals to these ParkNet therapists by neurologists.

OTHERUsual Care

No altered organisation of physiotherapy care in Parkinson's Disease

Sponsors

ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients with idiopathic PD, diagnosed according to the Brain Bank criteria of the UK Parkinson's Disease Society * Living independently in the community * Able to complete the trial questionnaires.

Exclusion criteria

* Atypical parkinsonian syndromes * Hoehn & Yahr stage 5 * Severe cognitive impairment * Presence of major psychiatric disorders * Severe co-morbidity (e.g. cancer) that interferes with daily functioning.

Design outcomes

Primary

MeasureTime frame
Modified MACTAR scale6 months

Secondary

MeasureTime frame
Costs6 months
Proportion of correct referrals (tertiary)6 months
Quality of physiotherapy(tertiary)6 months
Incidence of Falls (tertiary)6 months
ALDS (tertiary)6 months
SF-36 (tertiary)6 months
EQ-5D (tertiary)6 months
Satisfaction of patients and professionals (tertiary)6 months
Self Assessment Disability Scale (tertiary)6 months
Freezing of Gait Questionnaire {tertiary}6 months
Parkinson Activity Scale (secondary)6 months
4x3 meter walk test (tertiary)6 months
Single leg stance (tertiary)6 months
Posture and Gait score (tertiary)6 months
Timed Up and Go (tertiary)6 months
Falls Efficacy Scale {tertiary}6 months
9-hole pegboard test {tertiary}6 months
Health Anxiety and Depression Scale (tertiary)6 months
Physical activities assessed with the LAPAQ questionnaire (tertiary)6 months
Caregiver burden assessed with the Care Giver Strain Index (tertiary)6 months
PDQ-39 (Mobility Scale)6 months
6 meter walk test {tertiary}6 months

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026